Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: wlcnyc who wrote (111553)	3/23/2004 9:22:18 AM
From: wlcnyc	Respond to of 208838

More on CYTR - In Play® HIV vaccine (CYTR) 1.71: CytRx, Advanced BioScience Labs, and the University of Massachusetts Medical School announce that the HIV vaccine formulation developed by UMass and ABL and funded by the National Institute of Allergy and Infectious Diseases has been designated an investigational new drug by the FDA. UMass will conduct the Phase I clinical trial and begin recruiting patients shortly. ------------------------------------------------------------- CytRx shares rocket on HIV vaccine testing approval cbs.marketwatch.com;